UBS Group
ORIC icon

UBS Group’s Oric Pharmaceuticals ORIC Stock Holding History

UBS Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
222,923
+28,234
+15% +$256K ﹤0.01% 4943
2026
Q1 		$2.47M Sell
194,689
-540,169
-74% -$6.13M ﹤0.01% 4781
2025
Q4 		$6.01M Buy
734,858
+395,622
+117% +$4.55M ﹤0.01% 3832
2025
Q3 		$4.07M Buy
339,236
+240,230
+243% +$2.53M ﹤0.01% 4253
2025
Q2 		$1M Buy
99,006
+19,468
+24% +$131K ﹤0.01% 5451
2025
Q1 		$444K Buy
79,538
+4,609
+6% +$40.3K ﹤0.01% 5944
2024
Q4 		$605K Buy
74,929
+3,374
+5% +$31K ﹤0.01% 5706
2024
Q3 		$733K Sell
71,555
-9,252
-11% -$91.5K ﹤0.01% 4919
2024
Q2 		$571K Sell
80,807
-13,254
-14% -$119K ﹤0.01% 4906
2024
Q1 		$1.29M Buy
94,061
+53,088
+130% +$631K ﹤0.01% 4376
2023
Q4 		$377K Buy
40,973
+23,701
+137% +$171K ﹤0.01% 5323
2023
Q3 		$104K Sell
17,272
-4,996
-22% -$40.9K ﹤0.01% 5806
2023
Q2 		$173K Buy
+22,268
New +$126K ﹤0.01% 5586
2023
Q1 		– Sell
-4,433
Closed -$26.1K – 10155
2022
Q4 		$26.1K Buy
4,433
+4,300
+3,233% +$14.5K ﹤0.01% 7382
2022
Q3 		$0 Sell
133
-2,071
-94% -$8.29K ﹤0.01% 10759
2022
Q2 		$10K Buy
+2,204
New +$8.79K ﹤0.01% 7982
2022
Q1 		– Sell
-62,399
Closed -$917K – 10713
2021
Q4 		$917K Buy
62,399
+36,413
+140% +$568K ﹤0.01% 4470
2021
Q3 		$544K Buy
25,986
+18,747
+259% +$380K ﹤0.01% 4677
2021
Q2 		$128K Sell
7,239
-24,265
-77% -$532K ﹤0.01% 5694
2021
Q1 		$772K Buy
31,504
+29,977
+1,963% +$947K ﹤0.01% 4506
2020
Q4 		$52K Sell
1,527
-83
-5% -$2.38K ﹤0.01% 6145
2020
Q3 		$40K Sell
1,610
-1,234
-43% -$29.4K ﹤0.01% 5800
2020
Q2 		$96K Buy
+2,844
New +$90.8K ﹤0.01% 5344

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's ORIC Position: Q2 2026 in Review

UBS Group increased its Oric Pharmaceuticals (ORIC) stake by 15% in Q2 2026, buying an estimated $256K and bringing the position to 222,923 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #4943.

UBS Group first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $6.01M in Q4 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • UBS Group held 222,923 shares of Oric Pharmaceuticals worth $2.41M as of Q2 2026.
  • UBS Group bought 28,234 Oric Pharmaceuticals shares in Q2 2026, an estimated $256K.
  • Oric Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4943 holding.
  • UBS Group first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • UBS Group's Oric Pharmaceuticals position peaked at $6.01M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.